Patent Grant
11793626
This disclosure generally relates to devices, systems and methods that improve peripheral vision.
Intraocular Lenses (IOLs) may be used for restoring visual performance after a cataract or other ophthalmic procedure in which the natural crystalline lens is replaced with or supplemented by implantation of an IOL. When such a procedure changes the optics of the eye, generally a goal is to improve vision in the central field. Recent studies have found that, when a monofocal IOL is implanted, peripheral aberrations are changed, and that these aberrations differ significantly from those of normal, phakic eyes. The predominant change is seen with respect to peripheral astigmatism, which is the main peripheral aberration in the natural eye, followed by sphere, and then higher order aberrations. Such changes m ay have an impact on overall functional vision, including the ability to drive, the risk of falling, postural stability and/or detection ability.
There are also certain retinal conditions that reduce central vision, such as AMD or a central scotoma. Other diseases may impact central vision, even at a very young age, such as Stargardt disease, Best disease, and inverse retinitis pigmentosa. The visual outcome for patients suffering from these conditions can be improved by improving peripheral vision. Peripheral vision can also be degraded by Glaucoma. Glaucoma affects 2% of the population above the age of 40. Patients with glaucoma gradually lose peripheral vision as a result of damage to the optic nerve. Central vision may get degraded at very late stages of the disease. Significant disabilities in daily life can occur due to glaucoma, including problems with walking, balance, risk of falling and driving. Patients suffering from Glaucoma can benefit from IOLs that improve both central as well as peripheral vision.
The systems, methods and devices of the disclosure each have several innovative aspects, no single one of which is solely responsible for the desirable attributes disclosed herein.
Patients with central visual field loss caused by e.g. age-related macular degeneration (AMD) rely on their remaining peripheral vision to view objects in the external world. Usually, they develop a preferred retinal locus (PRL), an area on the peripheral retina where the optical image quality is higher than optical image quality at other areas of the retina. They view the PRL either by rotating the eye or the head, thus using eccentric fixation. However, vision at the PRL is much poorer, due to both retinal factors, such as, f or example, decreased density of ganglion cells and optical factors, such as, for example, light with the oblique incidence necessary to get to the PRL is degraded by oblique astigmatism and coma. Patients with AMD can receive substantial improvements in vision from refractive correction on their PRL, more so than healthy subjects at similar retinal eccentricity. Patients with Glaucoma who suffer from degraded peripheral visual quality can also benefit from IOLs that improve peripheral optical image quality. Current IOL technologies that are configured to correct refractive errors at the fovea can degrade peripheral optical image quality substantially as compared to the natural lenses. Accordingly, IOLs that can improve image quality at the fovea as well as the peripheral retina can be advantageous.
Various systems, methods and devices disclosed herein are directed towards intraocular lenses (IOLs) including, for example, posterior chamber IOLs, phakic IOLs and piggyback IOLs, which are configured to improve peripheral vision. For normal patients, e.g., uncomplicated cataract patients, peripheral vision may be balanced with good central vision in order to improve or maximize overall functional vision. For those patients having a pathological loss of central vision, peripheral vision may be improved or maximized for field angles 30-40 degrees with respect to the optic axis. For some patients, peripheral vision may be improved or maximized by taking into account the visual angle where the retina is healthy.
The systems, methods and devices may be better understood from the following detailed description when read in conjunction with the accompanying schematic drawings, which are for illustrative purposes only. The drawings include the following figures:
Patients suffering from AMD experience loss of central vision and rely on their peripheral vision to view objects in their environment. One way to aid patients with AMD currently is through the use of magnification. Magnification is usually accomplished by a high power loupe or telescope. Magnification can be achieved with implantable telescopes in one or both eyes. For example, a two-lens system can be employed to provide magnification for AMD patients. As another example, a lens system comprising a Lipshitz mirror telescope can be employed to provide magnification for AMD patients. However, the current solutions may not be configured to correct refractive errors at the fovea or at the peripheral retinal locations. Solutions for AMD patients can benefit from increasing visual quality at peripheral retinal location.
Glaucoma affects 2% of the population above age 40 and prevalence increases with age. Patients suffering from Glaucoma gradually lose peripheral vision as a result of damage to the optic nerve. As Glaucoma progresses, the central vision also gets affected. Glaucoma is usually diagnosed through a variety of methods including measuring intraocular pressure (IOP) and/or performing visual field tests (perimetry). Accordingly, IOLs visual field tests are configured to measure visual acuity for a variety of visual field angles between −30 degrees to 30 degrees. Patients suffering from Glaucoma gradually lose peripheral vision. Accordingly, Glaucoma patients can benefit from optical solutions that increase visual quality for peripheral vision.
Various IOLs that are currently available in the market while configured to provide good visual acuity for central vision can introduce refractive errors (e.g., defocus and/or astigmatism) in the peripheral vision. Accordingly, IOLs that can reduce peripheral refractive errors while also providing maintaining or increasing image quality at the fovea can be beneficial to patients with Glaucoma who may or may not suffer also from cataract. IOL designs that can reduce these peripheral refractive errors can have several benefits including but not limited to the following:
Various IOL designs configured to improve peripheral image quality are described in U.S. application Ser. No. 14/692,609 filed on Apr. 21, 2015 published as U.S. Publication No. 2015/0320547 which is incorporated by reference here in its entirety. Various IOL designs configured to improve peripheral image quality for patients with AMD are described in U.S. application Ser. No. 14/644,101 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0265399); Ser. No. 14/644,110 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/644,107 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/849,369 (filed on Sep. 9, 2015) and Ser. No. 14/644,082 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0250583). Each of the above-identified application is incorporated by reference herein in its entirety.
Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise at least one of redirection elements, refractive index gradient, multi-refraction elements, asymmetric Zernike surfaces or Fresnel diffractive elements. In various embodiments, the shape factor of the IOLs can be modified to correct errors in the peripheral retinal location. Furthermore, embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can be both symmetric (improving the peripheral field in all locations) and asymmetric (improving the area around the PRL).
Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise piggyback lenses that can improve peripheral MTF using thin and thick designs to reduce peripheral refractive errors, astigmatism, coma and other optical errors. Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise toric, aspheric, higher order aspheric, Zernike and biconic surfaces, overlaid on either meniscus, biconvex or biconcave designs. Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise piggyback lenses with Fresnel surfaces. In some embodiments, the principal plane of an existing IOL can be displaced to improve image quality at one or more peripheral retinal locations.
Embodiments of IOLs that are configured to improve image quality at one or more peripheral retinal locations can be configured to correcting astigmatism and coma that arise from oblique incidence. In addition to correcting astigmatism and coma arising from oblique incidence of light, it may be advantageous to provide embodiments of IOLs that can correct longitudinal chromatic aberrations to improve image quality at one or more peripheral retinal locations. Correcting longitudinal chromatic aberrations in addition to correcting astigmatism and coma that arise from oblique incidence of light can further improve image quality at peripheral retinal locations.
Various embodiments disclosed herein comprise an IOL including an achromatic optical element. For example, an IOL configured to correct peripheral aberrations through the use of shape factor, displacement and correct balancing of higher order aberrations can be combined with an achromatic optical element or an achromatic surface optimized for the power of the IOL. In various embodiments the achromatic surface can be disposed on the side of the IOL that has a lower slope. For example, in various embodiments, the achromatic surface can be disposed on the anterior side that is configured to receive incident light which may have a lower slope rather than the posterior side.
Various embodiments of IOLs disclosed herein are configured to correct peripheral refractive errors for visual field angles up to ±30-degrees. At least one of a shape factor, a placement of the IOL in the eye, curvature and/or a sphericity of the surfaces of the IOL disclosed herein can be adjusted such that residual peripheral refractive errors for visual field angles up to ±30-degrees when the IOL is implanted in the eye is less than a threshold amount. Various embodiments of IOLs disclosed herein can include an achromatic optical element. For example, an IOL configured to correct peripheral aberrations through the use of shape factor, displacement and balancing of higher order aberrations can be combined with an achromatic optical element or an achromatic surface optimized for the power of the IOL.
Embodiments of IOLs with Double A Sphere Design
Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise a meniscus lens in which both the anterior and posterior surfaces are aspheric (also referred to as Double A sphere Design (DAD)). To improve the image quality at one or more peripheral retinal locations, the meniscus lens can be implanted such that the principal plane of the lens is displaced by an amount such as, for example about 0.2 mm and about 0.6 mm posteriorly from the iris as compared to the position where a standard intraocular lens (e.g., a meniscus IOL) is implanted. In various embodiments, the meniscus lens can have a negative shape factor, wherein the first surface is concave and the second surface is convex. To correct longitudinal chromatic aberrations, a meniscus lens having a first surface that is concave and a second surface that is convex can include an achromatic surface placed on the anterior part that is flatter (or has a lower slope) as compared to the posterior surface. The meniscus (e.g., double a sphere design) lens including an achromatic surface can comprise:
Various embodiments of IOLs configured to improve image quality at one or more peripheral retinal locations can comprise a biconvex design (also referred to as BOSS herein) in which both the anterior and the posterior surfaces have similar curvatures. The anterior and the posterior surfaces can be aspheric. In various embodiments, embodiments of IOL having biconvex lens designs can be implanted such that the principal plane of the lens is displaced by an amount such as, for example about 0.5 mm and about 1.0 mm posteriorly from the iris as compared to the position where a standard IOL (e.g., a biconvex lens design) is implanted. The biconvex lens can have a shape factor close to zero, and a thickness between about 0.7 mm and about 1.0 mm. In various embodiments of IOLs with biconvex design, the achromatic surface can be placed on the anterior side or the posterior side, since both the anterior and posterior surface can have similar curvature in most practical implementations.
Various embodiments of biconvex lens designs are illustrated in FIGS. 35-38 in U.S. Publication No. 2015/0320547A1 which is incorporated by reference herein in its entirety herein for all that it discloses.
The achromatic optical element or surface integrated with the meniscus lens design (e.g., double aspheric lens design) or the biconvexlens design can comprise:
It is noted from
In various embodiments, the achromatic optical element or achromatic surface can be disposed on the less curved side. As discussed above, an advantage of introducing the achromatic optical element or achromatic surface comes from improved central visual performance, while still maintaining the good peripheral vision. The advantage of disposing the achromatic optical element or the achromatic surface on the less curved surface is observed from the figures below.
Several lenses according to the above described principles were manufactured and their performance measured in physical eye models. Examples of measured performance are depicted in
It is noted that for both 3 mm pupil condition and 5 mm pupil condition, the achromat optical element enhances optical performance for spatial frequencies above 50 cycles per mm, which is often used to illustrate on-axis performance. The on-axis best focus MTF for a spatial frequency of 50 cycles/mm for the meniscus lens with and without achromat optical element for 5 mm pupil condition and 3 mm pupil condition is shown in
In addition to substantial reduction in off-axis aberrations, such as, for example, oblique astigmatism, the surface geometries of the anterior and posteriors surfaces of the Double Aspheric Design (DAD) IOL can be configured to maintain on-axis image quality similar to existing monofocal IOLs that are configured to provide foveal vision. Various embodiments of IOLs (e.g., DAD IOLs) described herein can have a central axial thickness that is greater than the central axial thickness of existing monofocal IOLs that are configured to provide foveal vision. For example, various embodiments of IOLs described herein can have a central thickness of about 1.2 mm. As another example, various embodiments of IOLs described herein can have a central thickness greater than 0.5 mm and less than 2.0 mm, greater than or equal to about 0.6 mm and less than or equal to about 1.9 mm, greater than or equal to about 0.7 mm and less than or equal to about 1.8 mm, greater than or equal to about 0.9 mm and less than or equal to about 1.7 mm, greater than or equal to about 1.0 mm and less than or equal to about 1.6 mm, greater than or equal to about 1.1 mm and less than or equal to about 1.5 mm, greater than or equal to about 1.2 mm and less than or equal to about 1.4 mm, or any value in these ranges/sub-ranges. Various embodiments of the IOLs discussed herein (e.g., DAD IOL) can be vaulted when placed in the eye of the patient. For example, various embodiments of IOLs described herein can be vaulted by about 0.2 mm towards the retina as compared to existing monofocal IOLs that are configured to provide foveal vision. As another example, various embodiments of IOLs described herein can be vaulted towards the retina by an distance between about 0 mm and about 1.5 mm as compared to existing monofocal IOLs that are configured to provide foveal vision. The vault distance can be greater than or equal to about 0.05 mm and less than or equal to about 1.5 mm, greater than or equal to about 0.1 mm and less than or equal to about 1.4 mm, greater than or equal to about 0.2 mm and less than or equal to about 1.3 mm, greater than or equal to about 0.5 mm and less than or equal to about 1.2 mm, greater than or equal to about 0.75 mm and less than or equal to about 1.0 mm, or any value in these ranges/sub-ranges.
Various embodiments of DAD IOLs that can be used for cataract patients with or at risk for Age-related Macular Degeneration (AMD) and/or Glaucoma can comprise aspheric anterior and posterior surfaces. Various embodiments of DAD IOLs contemplated herein can be configured to provide good optical quality at the fovea as well at a location of the peripheral retina. Good optical quality at the location of the peripheral retina can be achieved by optimizing the surface geometries of the anterior and posterior surfaces of the IOL, by adjusting the central axial thickness of the IOL and/or by optimizing the distance of the anterior surface of the IOL from the iris. Currently, about 10% of patients undergoing cataract surgery have some form of AMD. Patients with AMD eventually lose their central vision, leaving only their peripheral vision. Therefore, IOLs configured to provide high image quality in the peripheral visual field, while simultaneously maintaining sufficient contrast ratio for central vision (also referred to herein as foveal vision), so that any remaining central vision can be used as long as possible are desirable. However, IOLs available commercially can exacerbate peripheral optical errors. Since patients with AMD can have their vision improved by correction of optical errors in the periphery, correction of peripheral optical errors represent an area of potentially improved visual quality of life.
Without subscribing to any particular theory, the anterior and posterior surface sag Z of various embodiments of DAD IOLs can be obtained from equation (1):
where r is the radial distance from the center of the lens, c is the curvature, k is the conic constant and a4, a6, a8, and a10 are the higher order aspheric terms.
The values of the central thickness and vault height for various embodiments of DAD IOLs can be selected keeping in view the following factors: (i) optical performance—IOLs with increased central thickness and higher vault height have increased optical performance; (ii) mechanical stability—which places an upper limit on vault height; (iii) ease of insertion in a human eye—smaller incision size (e.g., about 2.8 mm) is desirable which places a condition on central thickness; and (iv) functional optical zone size—increased central thickness of the IOL can provide an increase functional optical zone, which can desirable for AMD patients, many of who exhibit enlarged pupils. An example embodiment of a DAD IOL optimized based on the factors discussed above can have a vault height of about 0.45 mm, a central thickness of 1.2 mm and a functional optic zone of about 6 mm. Another example of a DAD IOL optimized to provide good foveal as well as peripheral visual quality can have a vault height between about 0.05 mm and about 1.5 mm, a central thickness between about 0.7 mm and about 1.5 mm and a functional optic zone having a size between about 4.5 mm and about 6.5 mm (e.g., a functional optic zone having a size of about 5 mm, or a functional optic zone having a size of about 6 mm).
Table 1 below provides the values of the coefficients that define the anterior and posterior surface of various embodiments of DAD IOLs having optical power from about 18 D to about 30 D. In Table 1, column A is the optical power in Diopters for various embodiments of the DAD IOL, column B indicates one of an anterior (Ant.) or a posterior (Post.) surface for various embodiment of the DAD IOL, column C is the central thickness in mm for various embodiment of the DAD IOL, column D is the vault height (towards the retina) in mm for various embodiment of the DAD IOL, column E is the radius of curvature of the respective surface (Ant. Or Post.) for various embodiment of the DAD IOL, column F is the conic constant k used to design the respective surface (Ant. Or Post.) for various embodiment of the DAD IOL, columns G, H and I are the higher order aspheric terms a4, a6, a8 and a10 used to design the respective surface (Ant. Or Post.) for various embodiment of the DAD IOL. For any given optical power, it is envisioned that specific embodiments include variations in any value in columns C through J of up to about 150%, or preferably up to about 10%, or up to about 5%. In specific embodiments, the range of optical powers can be between 5D and 40D, or preferably between from about 18D to about 30D, or between about 21D and about 27D.
The performance of an embodiment of a DAD JOL is compared with an existing monofocal JOL that is configured to provide good on-axis image quality. The comparison of the performance of the embodiment of the DAD JOL and the existing monofocal JOL was based on the following three metrics: on-axis MTF, off-axis astigmatism and simulated peripheral VA.
Simulated off-axis astigmatism is depicted in
Although the peripheral astigmatism is one of the sources of off-axis aberration, it does not fully describe peripheral off-axis image quality. Other peripheral aberrations such as peripheral defocus, coma, and other higher order aberrations can also degrade image quality. Therefore, a metric that relies on the area under the MTF for spatial frequencies up to the neurally relevant cutoff is used to characterize peripheral visual quality. The area under the MTF can be correlated with on-axis visual acuity. The area is then converted to an equivalent diopter value, which is converted to a VA loss score in log MAR with a factor of 0.15.
As discussed herein, correction of peripheral refractive errors and/or aberrations can improve peripheral vision. For example, patients with AMD can benefit by correction of peripheral refractive errors and/or aberrations.
Thus, compared to an existing monofocal IOL that is configured to provide good on-axis image quality (referred to herein as a ZCB IOL), the DAD IOL can give superior off-axis performance, while maintaining equal on-axis performance. The embodiments of the DAD IOL discussed herein can be configured to have increased tolerance to a large number surgery dependent variables as well as population variables. The design principles discussed herein can also be used to design and manufacture an intraocular lens that provides visual acuity for foveal vision (or central vision) as well as peripheral vision (e.g., for visual field angles up to 30 degrees) similar to the IOLs described in U.S. Provisional Application No. 62/385,702 filed on Sep. 9, 2016 titled “Intraocular Lenses with Improved Central and Peripheral Vision” which is incorporated herein by reference in its entirety is described below.
Various embodiments of the IOL 1350 can be configured such that the posterior surface 1353 is configured to provide most of the refractive power and the anterior surface 1351 is configured to correct for the spherical aberration introduced by the posterior surface 1353. In various embodiments of the IOL 1350 the anterior surface 1351 and/or the posterior surface 1353 can be aspheric. In such embodiments, the a sphericity of the posterior surface 1353 can be configured to introduce a significant amount of spherical aberration in the posterior surface. For example, the posterior surface 1353 can be configured to have spherical aberration in the range between about 0.5 μm and 1.3 μm (e.g., 1.11 μm). Accordingly, the anterior surface 1351 can be configured to have a negative spherical aberration in the range between about −0.5 μm and −1.3 μm to correct for the spherical aberration introduced by the posterior surface 1353 such that the total residual spherical aberration introduced by the IOL 1350 for a normal population of eyes is in the range between 0.1 μm and −0.05 μm fora 5 mm pupil. The apshericity of the anterior surface 1351 that corrects the spherical aberration introduced by the posterior surface 1353 can have a great impact on peripheral image quality. For example, the a sphericity of the positive surface 1353 and the anterior surface 1351 can be adjusted such that the average value for the total residual spherical aberration introduced by the IOL 1350 for a normal population of eyes can be less than about 0.05 μm for a 5 mm pupil.
The IOL 1350 can be configured to have a shape factor between −2 and −0.9. For example, the shape factor of the IOL 1350 can be less than or equal to −0.9 and greater than −1.0; less than or equal to −1.0 and greater than −1.1; less than or equal to −1.1 and greater than −1.2; less than or equal to −1.3 and greater than −1.4; less than or equal to −1.5 and greater than −1.6; less than or equal to −1.7 and greater than −1.8; less than or equal to −1.8 and greater than −1.9; less than or equal to −1.9 and greater than −2.0. The shape factor of the IOL 100 can be adjusted by adjusting a variety of parameters including but not limited to vault height of the IOL 1350, placement of the IOL 1350 in the eye, thickness of the IOL 1350 along the optical axis 1355, curvature of the posterior and anterior surfaces of the IOL 1350 and/or a sphericity of the posterior and anterior surfaces of the IOL 1350. In various embodiments, the vault height of the IOL 1350 can be increased by an amount between 0 and about 1.5 mm as compared to standard IOLs. As discussed above, the IOL 1350 can be vaulted posteriorly towards the retina by a distance between about 0 mm and about 1.5 mm as compared to standard IOLs. For example, in various embodiments the IOL 1350 can be implanted such that the principal plane of the IOL 1350 is displaced by an amount such as, for example about 0.01 mm and about 0.6 mm posteriorly from the iris as compared to the position where a standard intraocular lens (e.g., a meniscus IOL) is implanted. As another example, the IOL 1350 can be implanted such that the principal plane of the IOL 1350 is displaced by a distance of about 0.2 mm posteriorly from the iris as compared to the position where a standard intraocular lens is implanted. Vaulting the IOL 1350 posteriorly towards the retina can result in a shift of the principal plane of the IOL 1350 posteriorly.
It is noted that the shift of the principal plane for the IOL 1350 can be achieved by a variety of methods including but not limited to distributing the refractive power such that a majority of the refractive power is provided by the posterior surface, physically shifting the position of the IOL 1350 and/or increase in thickness of the IOL 1350. In various embodiments, the IOL 1350 can have a thickness that is about 0.1 mm to about 0.5 mm thicker than thickness of standard IOLs. For example, as discussed above, the central thickness of the IOL 1350 can be in the range between about 0.7 mm and about 1.5 mm.
As discussed above, the curvature of the posterior surface 1353 of the IOL 1350 is configured such that the posterior surface 1353 contributes more to the total refractive optical power provided by the IOL 1350 than the anterior surface 1351. For example, the curvature of the posterior surface 1353 can be configured to provide an optical power between about −20 Diopter and +20 Diopter. The curvature of the posterior surface 1353 and the anterior surface 1351 of the IOL 1350 can be configured such that the IOL 1350 has a shape factor between −2 and −0.9. The IOL 1350 when implanted in a normal human eye can provide a residual peripheral astigmatism less than about 1.5 Diopter at a visual field angle of about 30 degrees as compared to a residual peripheral astigmatism of about 3.0 Diopter at a visual field angle of about 30 degrees provided by a standard IOL currently available in the market when implanted in the normal human eye. Without subscribing to any particular theory, the residual peripheral astigmatism is a difference in diopters between tangential and sagittal peaks which is referred to optometrists as ‘C’. As another example, the IOL 1350 when implanted in a normal human eye can provide a residual peripheral defocus less than about 1.0 Diopter at a visual field angle of about 30 degrees as compared to a residual peripheral defocus of about 1.5 Diopter at a visual field angle of about 30 degrees provided by a standard IOL currently available in the market when implanted in the normal human eye.
Embodiments of the IOL 1350 can have optical characteristics similar to optical characteristic of other lens designs that are configured to improve peripheral image quality described in U.S. application Ser. No. 14/692,609 filed on Apr. 21, 2015 published as U.S. Publication No. 2015/0320547 which is incorporated by reference here in its entirety. The Glaucoma IOL can be configured as a dual-optic IOL or a piggyback IOL. In various embodiments, embodiments of the IOL 1350 can be configured as a meniscus lens, a biconvex lens, a plano-convex lens or any other possible shape. The embodiments of the IOL 1350 described herein can be combined with or replace one or more IOL designs configured to improve peripheral image quality for patients with AMD that are described in U.S. application Ser. No. 14/644,101 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0265399); Ser. No. 14/644,110 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/644,107 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/849,369 (filed on Sep. 9, 2015) and Ser. No. 14/644,082 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0250583) which are incorporated by reference herein for all that they describe.
Example Method of Designing an IOL
An example method of designing an IOL to correct for peripheral refractive errors is illustrated in
An initial shape factor of an IOL that provides good visual acuity for central vision is determined as shown in block 1503. The initial shape factor can b e similar to the shape factor of an appropriate standard IOL currently available that would provide good foveal vision for the patient. The initial shape factor can be iteratively adjusted to optimize peripheral refractive errors for visual field angles up to ±30-degrees without significantly decreasing visual acuity for central vision to determine a final shape factor as shown in block 1505. Adjusting the initial shape factor can include adjusting a curvature of the surfaces of the IOL, adjusting the a sphericity of the surfaces of the IOL, adjusting a central thickness of the IOL, adjusting a placement of the IOL in the eye. The final shape factor can be determined by placing a model of the IOL having the initial shape factor in a model eye and adjusting one or more parameters (e.g., thickness, curvature and/or a sphericity of the surfaces, shape, etc.) of the model IOL till residual peripheral errors (e.g., defocus an d astigmatism) for visual field angles up to ±30-degrees are below a threshold value. For example, the determined final shape factor of the IOL can provide a residual peripheral astigmatism less than 1.5 Diopter at a visual field angle of about 30 degrees as compared to a residual peripheral astigmatism of about 3.0 Diopter at a visual field angle of about 30 degrees provided by a lens having the initial shape factor. As another example, the determined final shape factor of the IOL can provide a residual peripheral defocus less than 1.0 Diopter at a visual field angle of about 30 degrees as compared to a residual peripheral defocus of about 1.5 Diopter at a visual field angle of about 30 degrees provided by a lens having the initial shape factor.
Peripheral astigmatism can be independent of the patient's biometric inputs. Accordingly, the determination of the final shape factor of the IOL that results in an optical power distribution that corrects for peripheral astigmatism can be independent of the patient's biometric inputs. In some embodiments, the final shape factor of the IOL can b e configured to correct peripheral astigmatism by providing additional cylinder power that compensates for peripheral astigmatism only at certain specific visual field angles (e.g., ±15 degrees, ±20 degrees, ±25 degrees, ±30 degrees). In some other embodiments, the final shape factor of the IOL can be configured to correct peripheral astigmatism by providing additional cylinder power that compensates for peripheral astigmatism at all visual field angles in an angular range (e.g., between ±15 degrees, between ±20 degrees, between ±25 degrees, between ±30 degrees). In some embodiments, the final shape factor of the IOL can be configured to correct defocus only at certain specific visual field angles (e.g., ±15 degrees, ±20 degrees, ±25 degrees, ±30 degrees). In some other embodiments, the final shape factor of the IOL can be configured to correct defocus at all visual field angles in an angular range (e.g., between ±15 degrees, between ±20 degrees, between ±25 degrees, between ±30 degrees).
The method of designing an IOL to correct for peripheral refractive errors can be implemented by a computer system 1600 illustrated in
The array of ordered values 1608 may comprise, for example, one or more ocular dimensions of an eye or plurality of eyes from a database, a desired refractive outcome, parameters of an eye model based on one or more characteristics of at least one eye, and data related to an IOL or set of IOLs such as a power, an aspheric profile, and/or a lens plane. In some embodiments, the sequence of instructions 1610 includes determining a position of an IOL, performing one or more calculations to determine a predicted refractive outcome based on an eye model and a ray tracing algorithm, comparing a predicted refractive outcome to a desired refractive outcome, and based on the comparison, repeating the calculation with an IOL having at least one of a different power, different design, and/or a different IOL location.
The computer system 1600 may be a general purpose desktop or laptop computer or may comprise hardware specifically configured performing the desired calculations. In some embodiments, the computer system 1600 is configured to be electronically coupled to another device such as a phacoemulsification console or one or more instruments for obtaining measurements of an eye or a plurality of eyes. In other embodiments, the computer system 1600 is a handheld device that may be adapted to be electronically coupled to one of the devices just listed. In yet other embodiments, the computer system 1600 is, or is part of, refractive planner configured to provide one or more suitable intraocular lenses for implantation based on physical, structural, and/or geometric characteristics of an eye, and based on other characteristics of a patient or patient history, such as the age of a patient, medical history, history of ocular procedures, life preferences, and the like.
In certain embodiments, the system 1600 includes or is part a phacoemulsification system, laser treatment system, optical diagnostic instrument (e.g, autorefractor, aberrometer, and/or corneal topographer, or the like). For example, the computer readable memory 1604 may additionally contain instructions for controlling the handpiece of a phacoemulsification system or similar surgical system. Additionally or alternatively, the computer readable memory 1604 may additionally contain instructions for controlling or exchanging data with an autorefractor, aberrometer, tomographer, and/or topographer, or the like.
In some embodiments, the system 1600 includes or is part of a refractive planner. The refractive planner may be a system for determining one or more treatment options for a subject based on such parameters as patient age, family history, vision preferences (e.g., near, intermediate, distant vision), activity type/level, past surgical procedures.
An achromatic optical element or an achromatic surface as described herein can be integrated with other embodiments of IOLs that improve peripheral vision that are described in U.S. application Ser. No. 14/692,609 filed on Apr. 21, 2015 published as U. S. Publication No. 2015/0320547 which is incorporated by reference here in its entirety. An achromatic optical element or an achromatic surface as described herein can be integrated with the various IOL designs configured to that improve peripheral image quality for patients with AMD that are described in U.S. application Ser. No. 14/644,101 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0265399); Ser. No. 14/644,110 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/644,107 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0297342); Ser. No. 14/849,369 (filed on Sep. 9, 2015) and Ser. No. 14/644,082 (filed on Mar. 10, 2015, Published as U.S. Publication No. 2015/0250583) which are incorporated by reference herein for all that they describe.
The achromatic profile step height can be adjusted to optimize performance for the peripheral region of interest to aid patients with AMD. In some embodiments, the step height can be reduced by a factor of cosine of the angle of the preferred retinal locus, to account for the oblique incidence.
In some embodiments, the achromatic zone size can be limited to portions of the pupil while leaving some portions of the pupil free of the achromatic optical element to provide clear region to view or inspect the retina. In some embodiments, the achromatic optical element can be configured such that the central parts of the achromat contribute to on-axis performance and peripheral parts of the achromat contribute to off-axis performance.
Various embodiments of the lenses and the achromats can comprise a material that can block specific parts of the spectrum. For example, the lenses and achromats can comprise a material that can block potentially AMD-inducing blue light. The peak wavelength selected to design various embodiments of the lenses and achromats can be based on the material used to manufacture the lenses and achromats. For example, if the lenses and achromats comprise a material that can block potentially AMD-inducing blue light, the design wavelength can be selected to be greater than 550 nm, in order to optimize the amount of light in the first order focus.
Various concepts, systems and methods described herein can also be used for patients without AMD who wish to improve peripheral vision while gaining superior on-axis vision.
The above presents a description of the best mode contemplated of carrying out the concepts disclosed herein, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use the concepts described herein. The systems, methods and devices disclosed herein are, however, susceptible to modifications and alternate constructions from that discussed above which are fully equivalent. Consequently, it is not the intention to limit the scope of this disclosure to the particular embodiments disclosed. On the contrary, the intention is to cover modifications and alternate constructions coming within the spirit and scope of the present disclosure as generally expressed by the following claims, which particularly point out and distinctly claim the subject matter of the implementations described herein.
Although embodiments have been described and pictured in an example form with a certain degree of particularity, it should be understood that the present disclosure has been made by way of example, and that numerous changes in the details of construction and combination and arrangement of parts and steps may be made without departing from the spirit and scope of the disclosure as set forth in the claims hereinafter.
As used herein, the term “processor” refers broadly to any suitable device, logical block, module, circuit, or combination of elements for executing instructions. For example, the processor 1602 can include any conventional general purpose single- or multi-chip microprocessor such as a Pentium® processor, a MIPS® processor, a Power PC® processor, AMD® processor, ARM processor, or an ALPHA® processor. In addition, the processor 302 can include any conventional special purpose microprocessor such as a digital signal processor. The various illustrative logical blocks, modules, and circuits described in connection with the embodiments disclosed herein can be implemented or performed with a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. Processor 1602 can be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.
Computer readable memory 1604 can refer to electronic circuitry that allows information, typically computer or digital data, to be stored and retrieved. Computer readable memory 1604 can refer to external devices or systems, for example, disk drives or solid state drives. Computer readable memory 1604 can also refer to fast semiconductor storage (chips), for example, Random Access Memory (RAM) or various forms of Read Only Memory (ROM), which are directly connected to the communication bus or the processor 1602. Other types of memory include bubble memory and core memory. Computer readable memory 1604 can be physical hardware configured to store information in a non-transitory medium.
Methods and processes described herein may be embodied in, and partially or fully automated via, software code modules executed by one or more general and/or special purpose computers. The word “module” can refer to logic embodied in hardware and/or firmware, or to a collection of software instructions, possibly having entry and exit points, written in a programming language, such as, for example, C or C++. A software module may be compiled and linked into an executable program, installed in a dynamically linked library, or may be written in an interpreted programming language such as, for example, BASIC, Perl, or Python. It will be appreciated that software modules may be callable from other modules or from themselves, and/or may be invoked in response to detected events or interrupts. Software instructions may be embedded in firmware, such as an erasable programmable read-only memory (EPROM). It will be further appreciated that hardware modules may comprise connected logic units, such as gates and flip-flop s, and/or may comprised programmable units, such as programmable gate arrays, application specific integrated circuits, and/or processors. The modules described herein can be implemented as software modules, but also may be represented in hardware and/or firmware. Moreover, although in some embodiments a module may be separately compiled, in other embodiments a module may represent a subset of instructions of a separately compiled program, and may not have an interface available to other logical program units.
In certain embodiments, code modules may be implemented and/or stored in any type of computer-readable medium or other computer storage device. In some systems, data (and/or metadata) input to the system, data generated by the system, and/or data used by the system can be stored in any type of computer data repository, such as a relational database and/or flat file system. Any of the systems, methods, and processes described herein may include an interface configured to permit interaction with users, operators, other systems, components, programs, and so forth.
This application is a continuation of and claims priority to U.S. patent application Ser. No. 16/818,942, filed Mar. 13, 2020, which is a divisional of and claims priority to U.S. patent application Ser. No. 15/456,356, filed Mar. 10, 2017, now U.S. Pat. No. 10,588,738, which is a non-provisional of and claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/307,241, filed on Mar. 11, 2016, titled “ACHROMAT INTRAOCULAR LENSES THAT IMPROVE PERIPHERAL VISIONS.” This application also claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/385,702, filed on Sep. 9, 2016, titled “INTRAOCULAR LENSES WITH IMPROVED CENTRAL AND PERIPHERAL VISION.” The entire content of each of the above identified applications is incorporated by reference herein in its entirety for all it discloses and is made part of this specification.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3367734 | Karl et al. | Feb 1968 | A |
| 4206969 | Cobb et al. | Jun 1980 | A |
| 4581031 | Koziol et al. | Apr 1986 | A |
| 4592630 | Okazaki | Jun 1986 | A |
| 4624538 | MacFarlane | Nov 1986 | A |
| 4637697 | Freeman | Jan 1987 | A |
| 4642112 | Freeman | Feb 1987 | A |
| 4648878 | Kelman | Mar 1987 | A |
| 4655565 | Freeman | Apr 1987 | A |
| 4666446 | Koziol et al. | May 1987 | A |
| 4778462 | Grendahl | Oct 1988 | A |
| 4795462 | Grendahl | Jan 1989 | A |
| 4798608 | Grendahl | Jan 1989 | A |
| 4798609 | Grendahl | Jan 1989 | A |
| 4828558 | Kelman | May 1989 | A |
| 4932970 | Portney | Jun 1990 | A |
| 4995714 | Cohen | Feb 1991 | A |
| 4995715 | Cohen | Feb 1991 | A |
| 5016977 | Baude et al. | May 1991 | A |
| 5056908 | Cohen | Oct 1991 | A |
| 5066301 | Wiley | Nov 1991 | A |
| 5089023 | Swanson | Feb 1992 | A |
| 5096285 | Silberman | Mar 1992 | A |
| 5114220 | Baude et al. | May 1992 | A |
| 5117306 | Cohen | May 1992 | A |
| 5120120 | Cohen | Jun 1992 | A |
| 5121979 | Cohen | Jun 1992 | A |
| 5121980 | Cohen | Jun 1992 | A |
| 5144483 | Cohen | Sep 1992 | A |
| 5225858 | Portney | Jul 1993 | A |
| 5229797 | Futhey et al. | Jul 1993 | A |
| 5354334 | Fedorov et al. | Oct 1994 | A |
| 5549669 | Jansen | Aug 1996 | A |
| 5652638 | Roffman et al. | Jul 1997 | A |
| 5683457 | Gupta et al. | Nov 1997 | A |
| 5699142 | Lee et al. | Dec 1997 | A |
| 5715091 | Meyers | Feb 1998 | A |
| 5728156 | Gupta et al. | Mar 1998 | A |
| 5748282 | Freeman | May 1998 | A |
| 5760871 | Kosoburd et al. | Jun 1998 | A |
| 5777719 | Williams et al. | Jul 1998 | A |
| 5796462 | Roffman et al. | Aug 1998 | A |
| 5968094 | Werblin et al. | Oct 1999 | A |
| 5969790 | Onufryk | Oct 1999 | A |
| 6126283 | Wen et al. | Oct 2000 | A |
| 6126286 | Portney | Oct 2000 | A |
| 6139145 | Israel | Oct 2000 | A |
| 6142625 | Sawano et al. | Nov 2000 | A |
| 6183084 | Chipman et al. | Feb 2001 | B1 |
| 6197057 | Peyman et al. | Mar 2001 | B1 |
| 6210005 | Portney | Apr 2001 | B1 |
| 6338559 | Williams et al. | Jan 2002 | B1 |
| 6457826 | Lett | Oct 2002 | B1 |
| 6464355 | Gil | Oct 2002 | B1 |
| 6464725 | Skottun et al. | Oct 2002 | B2 |
| 6474814 | Griffin | Nov 2002 | B1 |
| 6488708 | Sarfarazi | Dec 2002 | B2 |
| 6491721 | Freeman et al. | Dec 2002 | B2 |
| 6527389 | Portney | Mar 2003 | B2 |
| 6533416 | Fermigier et al. | Mar 2003 | B1 |
| 6533814 | Jansen | Mar 2003 | B1 |
| 6536899 | Fiala | Mar 2003 | B1 |
| 6537317 | Steinert et al. | Mar 2003 | B1 |
| 6547822 | Lang | Apr 2003 | B1 |
| 6551354 | Ghazizadeh et al. | Apr 2003 | B1 |
| 6554859 | Lang et al. | Apr 2003 | B1 |
| 6557992 | Dwyer et al. | May 2003 | B1 |
| 6609793 | Norrby et al. | Aug 2003 | B2 |
| 6705729 | Piers et al. | Mar 2004 | B2 |
| 6808262 | Chapoy et al. | Oct 2004 | B2 |
| 6830332 | Piers et al. | Dec 2004 | B2 |
| 6846326 | Zadno-Azizi et al. | Jan 2005 | B2 |
| 6849091 | Cumming | Feb 2005 | B1 |
| 6851803 | Wooley et al. | Feb 2005 | B2 |
| 6913620 | Lipshitz | Jul 2005 | B2 |
| 6923539 | Simpson et al. | Aug 2005 | B2 |
| 6923540 | Ye et al. | Aug 2005 | B2 |
| 6972033 | McNicholas | Dec 2005 | B2 |
| 6986578 | Jones | Jan 2006 | B2 |
| 7025456 | Morris et al. | Apr 2006 | B2 |
| 7025460 | Smitth, III et al. | Apr 2006 | B2 |
| 7036931 | Lindacher et al. | May 2006 | B2 |
| 7037338 | Nagamoto | May 2006 | B2 |
| 7048760 | Cumming | May 2006 | B2 |
| 7061693 | Zalevsky | Jun 2006 | B2 |
| 7073906 | Portney | Jul 2006 | B1 |
| 7137702 | Piers et al. | Nov 2006 | B2 |
| 7156516 | Morris et al. | Jan 2007 | B2 |
| 7186266 | Peyman | Mar 2007 | B2 |
| 7188949 | Bandhauer et al. | Mar 2007 | B2 |
| 7217289 | Coronco | May 2007 | B2 |
| 7238201 | Portney et al. | Jul 2007 | B2 |
| 7287852 | Fiala | Oct 2007 | B2 |
| 7293873 | Dai et al. | Nov 2007 | B2 |
| 7365917 | Zalevsky | Apr 2008 | B2 |
| 7377640 | Piers et al. | May 2008 | B2 |
| 7410500 | Claoue | Aug 2008 | B2 |
| 7441894 | Zhang et al. | Oct 2008 | B2 |
| 7475986 | Dai et al. | Jan 2009 | B2 |
| 7488069 | Hull | Feb 2009 | B2 |
| 7503655 | Smith et al. | Mar 2009 | B2 |
| 7615073 | Deacon et al. | Nov 2009 | B2 |
| 7665842 | Ho et al. | Feb 2010 | B2 |
| 7766482 | Smith, III et al. | Aug 2010 | B2 |
| 7871162 | Weeber | Jan 2011 | B2 |
| 7997727 | Ho et al. | Aug 2011 | B2 |
| 8057034 | Ho et al. | Nov 2011 | B2 |
| 8062361 | Nguyen et al. | Nov 2011 | B2 |
| 8201943 | Hammer et al. | Jun 2012 | B2 |
| 8206442 | Sel et al. | Jun 2012 | B2 |
| 8262728 | Zhang et al. | Sep 2012 | B2 |
| 8382832 | Deacon et al. | Feb 2013 | B2 |
| 8430508 | Weeber | Apr 2013 | B2 |
| 8540365 | Varnas | Sep 2013 | B2 |
| 8862447 | Weeber | Oct 2014 | B2 |
| 9345570 | Sieber et al. | May 2016 | B2 |
| 10016270 | Rosen et al. | Jul 2018 | B2 |
| 10327888 | Rosen et al. | Jun 2019 | B2 |
| 10456242 | Rosen et al. | Oct 2019 | B2 |
| 10588739 | Rosen et al. | Mar 2020 | B2 |
| 10758340 | Li et al. | Sep 2020 | B2 |
| 11096778 | Rosen et al. | Aug 2021 | B2 |
| 11331181 | Rosen et al. | May 2022 | B2 |
| 11517423 | Rosen et al. | Dec 2022 | B2 |
| 11534291 | Rosen et al. | Dec 2022 | B2 |
| 11660183 | Rosen et al. | May 2023 | B2 |
| 20020044255 | Ye | Apr 2002 | A1 |
| 20020101564 | Herrick | Aug 2002 | A1 |
| 20020118337 | Perrott et al. | Aug 2002 | A1 |
| 20020176049 | Sakai et al. | Nov 2002 | A1 |
| 20030076478 | Cox | Apr 2003 | A1 |
| 20030078656 | Nguyen | Apr 2003 | A1 |
| 20030171808 | Phillips | Sep 2003 | A1 |
| 20040085515 | Roffman et al. | May 2004 | A1 |
| 20040106992 | Lang et al. | Jun 2004 | A1 |
| 20040111153 | Woods et al. | Jun 2004 | A1 |
| 20040156014 | Piers et al. | Aug 2004 | A1 |
| 20050043794 | Geraghty et al. | Feb 2005 | A1 |
| 20050096226 | Stock et al. | May 2005 | A1 |
| 20050128432 | Altmann | Jun 2005 | A1 |
| 20050203619 | Altmann | Sep 2005 | A1 |
| 20050209692 | Zhang | Sep 2005 | A1 |
| 20060009816 | Fang et al. | Jan 2006 | A1 |
| 20060030938 | Altmann | Feb 2006 | A1 |
| 20060058874 | Peli | Mar 2006 | A1 |
| 20060066808 | Blum et al. | Mar 2006 | A1 |
| 20060098162 | Bandhauer et al. | May 2006 | A1 |
| 20060109421 | Ye et al. | May 2006 | A1 |
| 20060116763 | Simpson | Jun 2006 | A1 |
| 20060116764 | Simpson | Jun 2006 | A1 |
| 20060116765 | Blake et al. | Jun 2006 | A1 |
| 20060158611 | Piers et al. | Jul 2006 | A1 |
| 20060227286 | Hong | Oct 2006 | A1 |
| 20060229720 | Glazier et al. | Oct 2006 | A1 |
| 20060238702 | Glick et al. | Oct 2006 | A1 |
| 20060244904 | Hong et al. | Nov 2006 | A1 |
| 20060247766 | Marin | Nov 2006 | A1 |
| 20070052920 | Stewart et al. | Mar 2007 | A1 |
| 20070093891 | Tabernero | Apr 2007 | A1 |
| 20070129803 | Cumming et al. | Jun 2007 | A1 |
| 20070168027 | Brady et al. | Jul 2007 | A1 |
| 20070171362 | Simpson et al. | Jul 2007 | A1 |
| 20070182924 | Hong et al. | Aug 2007 | A1 |
| 20070268453 | Hong et al. | Nov 2007 | A1 |
| 20080030677 | Simpson | Feb 2008 | A1 |
| 20080147185 | Hong et al. | Jun 2008 | A1 |
| 20080161913 | Brady et al. | Jul 2008 | A1 |
| 20080161914 | Brady et al. | Jul 2008 | A1 |
| 20080212024 | Lai | Sep 2008 | A1 |
| 20080269882 | Simpson et al. | Oct 2008 | A1 |
| 20080269883 | Das et al. | Oct 2008 | A1 |
| 20080269884 | Vannoy | Oct 2008 | A1 |
| 20080269885 | Simpson | Oct 2008 | A1 |
| 20080269886 | Simpson et al. | Oct 2008 | A1 |
| 20080269890 | Simpson et al. | Oct 2008 | A1 |
| 20080312738 | Wanders | Dec 2008 | A1 |
| 20090018652 | Hermans et al. | Jan 2009 | A1 |
| 20090062911 | Bogaert | Mar 2009 | A1 |
| 20090164008 | Hong et al. | Jun 2009 | A1 |
| 20090187242 | Weeber et al. | Jul 2009 | A1 |
| 20090198326 | Zhou et al. | Aug 2009 | A1 |
| 20090204211 | Angelopoulos et al. | Aug 2009 | A1 |
| 20090210054 | Weeber et al. | Aug 2009 | A1 |
| 20090234448 | Weeber et al. | Sep 2009 | A1 |
| 20090268155 | Weeber | Oct 2009 | A1 |
| 20090292354 | Gontijo et al. | Nov 2009 | A1 |
| 20090295295 | Shannon et al. | Dec 2009 | A1 |
| 20090323020 | Zhao et al. | Dec 2009 | A1 |
| 20100016961 | Hong et al. | Jan 2010 | A1 |
| 20100079723 | Kingston et al. | Apr 2010 | A1 |
| 20100091244 | Volk | Apr 2010 | A1 |
| 20100100177 | Zhao | Apr 2010 | A1 |
| 20100100178 | Weeber et al. | Apr 2010 | A1 |
| 20100157240 | Schmid et al. | Jun 2010 | A1 |
| 20100161048 | Schaper, Jr. | Jun 2010 | A1 |
| 20100188636 | Pinto et al. | Jul 2010 | A1 |
| 20100204788 | Van Noy | Aug 2010 | A1 |
| 20110130833 | Scott et al. | Jun 2011 | A1 |
| 20110153014 | Zhang et al. | Jun 2011 | A1 |
| 20110279912 | Fiala | Nov 2011 | A1 |
| 20120262670 | Hong et al. | Oct 2012 | A1 |
| 20120277857 | Purchase et al. | Nov 2012 | A1 |
| 20130013060 | Zadno-Azizi et al. | Jan 2013 | A1 |
| 20130211515 | Blum et al. | Aug 2013 | A1 |
| 20130226294 | Van Der Mooren et al. | Aug 2013 | A1 |
| 20140022649 | Eckhardt | Jan 2014 | A1 |
| 20140168602 | Weeber et al. | Jun 2014 | A1 |
| 20140253877 | Li et al. | Sep 2014 | A1 |
| 20150005877 | Wanders | Jan 2015 | A1 |
| 20150250583 | Rosen et al. | Sep 2015 | A1 |
| 20150250585 | Rosen et al. | Sep 2015 | A1 |
| 20150265399 | Rosen et al. | Sep 2015 | A1 |
| 20150297342 | Rosen et al. | Oct 2015 | A1 |
| 20150320547 | Rosen et al. | Nov 2015 | A1 |
| 20160067037 | Rosen et al. | Mar 2016 | A1 |
| 20160161364 | Alarcon Heredia et al. | Jun 2016 | A1 |
| 20160193039 | Qureshi | Jul 2016 | A1 |
| 20160193040 | Qureshi et al. | Jul 2016 | A1 |
| 20180318069 | Rosen et al. | Nov 2018 | A1 |
| 20210378816 | Rosen et al. | Dec 2021 | A1 |
| 20230099097 | Rosen et al. | Mar 2023 | A1 |
| 20230105831 | Rosen et al. | Apr 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 0457553 | Nov 1991 | EP |
| 458508 | Nov 1991 | EP |
| 681198 | Nov 1995 | EP |
| 0926531 | Jun 1999 | EP |
| 949529 | Oct 1999 | EP |
| 1818023 | Aug 2007 | EP |
| 1284687 | Dec 2007 | EP |
| 1310267 | Jan 2008 | EP |
| 1424049 | Jun 2009 | EP |
| 9222264 | Dec 1992 | WO |
| 9303409 | Feb 1993 | WO |
| 0019906 | Apr 2000 | WO |
| 0163344 | Aug 2001 | WO |
| 0182839 | Nov 2001 | WO |
| 0189424 | Nov 2001 | WO |
| 0221194 | Mar 2002 | WO |
| 03000154 | Jan 2003 | WO |
| 03009053 | Jan 2003 | WO |
| 03022137 | Mar 2003 | WO |
| 2004034129 | Apr 2004 | WO |
| 2004049979 | Jun 2004 | WO |
| 2004068214 | Aug 2004 | WO |
| 2004090611 | Oct 2004 | WO |
| 2004096014 | Nov 2004 | WO |
| 05019906 | Mar 2005 | WO |
| 06025726 | Mar 2006 | WO |
| 2006047698 | May 2006 | WO |
| 06060477 | Jun 2006 | WO |
| 2006060480 | Jun 2006 | WO |
| 2006067255 | Jun 2006 | WO |
| 2007092948 | Aug 2007 | WO |
| 2007133384 | Nov 2007 | WO |
| 2008045847 | Apr 2008 | WO |
| 2008065362 | Jun 2008 | WO |
| 2009076670 | Jun 2009 | WO |
| 2009142961 | Nov 2009 | WO |
| 2010054255 | May 2010 | WO |
| 2012074742 | Jun 2012 | WO |
| 2012083143 | Jun 2012 | WO |
| 2013028992 | Feb 2013 | WO |
| 2013059041 | Apr 2013 | WO |
| 2013105855 | Jul 2013 | WO |
| 2014102352 | Jul 2014 | WO |
| 2015136375 | Sep 2015 | WO |
| 2015136380 | Sep 2015 | WO |
| Entry |
|---|
| Alfonso J.F., et al., “Prospective Study of the Acri.LISA Bifocal Intraocular Lens,” Journal of Cataract Refractive Surgery, Nov. 2007, vol. 33 (11), pp. 1930-1935. |
| Atchison D.A., et al., “Shape of the Retinal Surface in Emmetropia and Myopia,” Investigative Ophthalmology & Visual Science, Aug. 2005, vol. 46 (8), pp. 2698-2707. |
| Baskaran K., et al., “Benefit of Adaptive Optics Aberration Correction at Preferred Retinal Locus,” Optometry and Vision Science, Sep. 2012, vol. 89 (9), pp. 1417-1423. |
| Buralli D.A., et al., “Optical Performance Of Holographic Kinoforms,” Applied Optics, Mar. 1989, vol. 28 (5), pp. 976-983. |
| Canovas C., et al., “Hybrid Adaptive-Optics Visual Simulator,” Optical Letters, Jan. 15, 2010, vol. 35 (2), pp. 196-198. |
| Cohen A.L., “Practical Design of a Bifocal Hologram Contact Lens or Intraocular Lens,” Applied Optics, Jul. 1, 1992, vol. 31 (19), pp. 3750-3754. |
| Diffractive Lenses for Extended Depth of Focus and Presbyopic Correction, Presentation from Wavefront Congress held on Feb. 15, 2008, Rochester, New York. |
| Doskolovich L.L., et al., “Special Diffractive Lenses,” Lens and Optical Systems Design, Apr. 1992, vol. 1780, pp. 393-402. |
| Escudero-Sanz I., et al., “Off-Axis Aberrations of a Wide-Angle Schematic Eye Model,” Journal of the Optical Society of America. A, Optics, Image Science, and Vision, Aug. 1999, vol. 16 (8), pp. 1881-1891. |
| Hoffmann, P.C., et al., “Analysis of Biometry and Prevalence Data for Corneal Astigmatism in 23 239 Eyes,” Journal of Cataract and Refractive Surgery, Sep. 2010, vol. 36(9), pp. 1479-1485. |
| Jaeken B., et al., “Comparison of the Optical Image Quality in the Periphery of Phakic and Pseudophakic Eyes,” Investigative Ophthalmology & Visual Science, May 1, 2013, vol. 54 (5), pp. 3594-3599. |
| Jafari-Nodoushan M., et al., “Control-Flow Checking Using Branch Instructions,” IEEE/IFIP International Conference On Embedded and Ubiquitous Computing, Dec. 17-20, 2008, pp. 66-72. |
| Lewis P., et al., “Resolution of Static and Dynamic Stimuli in the Peripheral Visual Field,” Vision Research, Aug. 15, 2011, vol. 51 (16), pp. 1829-1834. |
| Liou H.L., et al., “Anatomically Accurate, Finite Model Eye for Optical Modeling,” Journal of Optical Society of America, Aug. 1997, vol. 14 (8), pp. 1684-1695. |
| Liou H.L., et al.,“The Prediction of Spherical Aberration with Schematic Eyes,” Ophthalmic and Physiological Optics, Jan. 1996, vol. 16 (4), pp. 348-354. |
| Lundstroma L., et al., “Symmetries in Peripheral Ocular Aberrations,” Journal of Modern Optics, Mar. 16, 2011, vol. 58 (19-20), pp. 1690-1695. |
| Marsack J.D., et al., “Metrics of Optical Quality Derived from Wave Aberrations Predict Visual Performance,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 322-328. |
| Monsoriu J.A., et al., “Devil's Lenses,” Optics Express, Oct. 17, 2007, vol. 15 (21), pp. 13858-13864. |
| Norrby S., et al., “Model Eyes for Evaluation of Intraocular Lenses,” Applied Optics, Sep. 7, 2007, vol. 46 (26), pp. 6595-6605. |
| Oh N., et al., “Control-Flow Checking by Software Signatures,” IEEE Transactions on Reliability, Mar. 2, 2002, vol. 51 (2), pp. 111-122. |
| Piers P.A., et al., “Eye Models for the Prediction of Contrast Vision in Patients with New Intraocular Lens Designs,” Optics Letters, Apr. 1, 2004, vol. 29 (7), pp. 733-735. |
| Piers P.A., et al., “Theoretical Comparison of Aberration-Correcting Customized and Aspheric Intraocular Lenses,” Journal of Refractive Surgery, Apr. 2007, vol. 23 (4), pp. 374-384. |
| Rosen R., et al., “Adaptive Optics for Peripheral Vision,” Journal of Modern Optics, Jul. 10, 2012, vol. 59 (12), pp. 1064-1070. |
| Rosen R., et al., “Evaluating the Peripheral Optical Effect of Multifocal Contact Lenses,” Ophthalmic and Physiological Optics, Nov. 2012, vol. 32 (6), pp. 527-534. |
| Rosen R., et al., “Have We Misinterpreted the Study of Hoogerheide Et Al. (1971)?,” Optometry and Vision Science, Aug. 2012, vol. 89 (8), pp. 1235-1237. |
| Rosen R., et al., “Sign-dependent Sensitivity to Peripheral Defocus for Myopes Due to Aberrations,” Investigative Ophthalmology & Visual Science, Oct. 17, 2012, vol. 53 (11), pp. 7176-7182. |
| Rosen R., et al., “Influence of Optical Defocus on Peripheral Vision,” Visual Psychophysics and Physiological Optics, Jan. 2011, vol. 52 (1), pp. 318-323. |
| Rosen R., “Peripheral Vision: Adaptive Optics and Psychophysics,” Doctoral Thesis Department of Applied Physics Royal Institute of Technology Stockholm, Sweden Apr. 2013, 86 pages. |
| Siedlecki D., et al., “Radial Gradient index Intraocular Lens: a Theoretical Model,” Journal of Modern Optics, Feb. 20-Mar. 10, 2008, vol. 55 (4-5), pp. 639-647. |
| Terwee T., et al., “Visualization of the Retinal Image in an Eye Model With Spherical and Aspheric, Diffractive, and Refractive Multifocal Intraocular Lenses,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 223-232. |
| Van Den Berg T.J., “Analysis of Intraocular Straylight, Especially in Relation to Age,” Optometry and Vision Science, Feb. 1995, vol. 72 (2), pp. 52-59. |
| Van Meeteren A., “Calculations on the Optical Modulation Transfer Function of the Human Eye for White Light,” Optica Acta, May 1974, vol. 21 (5), pp. 395-412. |
| Villegas E.A., et al., “Correlation between Optical and Psychophy, Sical Parameters as a Function of Defocus,” Optometry and Vision Science, Jan. 1, 2002, vol. 79 (1), pp. 60-67. |
| Number | Date | Country | |
|---|---|---|---|
| 20220047382 A1 | Feb 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62385702 | Sep 2016 | US | |
| 62307241 | Mar 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16818942 | Mar 2020 | US |
| Child | 17452986 | US | |
| Parent | 15456356 | Mar 2017 | US |
| Child | 16818942 | US |
